Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells

Marta Nardella1, Loredana Guglielmi1, Carla Musa1, Ilaria Iannetti1, Giovanna Maresca1, Donatella Amendola2, Manuela Porru3, Elisabetta Carico4, Giuseppe Sessa5, Rosalba Camerlingo5, Carlo Dominici6, Francesca Megiorni6, Marika Milan1, Claudia Bearzi1,8, Roberto Rizzi1,8, Giuseppe Pirozzi15, Carlo Leonetti3, Barbara Bucci2, Delio Mercanti1, Armando Felsani1, Igea D’Agnano1

1Institute of Cell Biology and Neurobiology-CNR, Monterotondo, Rome, Italy
2S.Pietro Hospital Fatebenefratelli, Rome, Italy
3Regina Elena Cancer Institute, Rome, Italy
4UOD Cytopathology, Department of Molecular and Clinical Medicine, Faculty of Medicine and Psychology, Sapienza University, Rome, Italy
5Department of Experimental Oncology, National Cancer Institute –IRCCS “Fondazione G. Pascale”, Naples, Italy
6Department of Paediatrics and Infantile Neuropsychiatry, Sapienza University, Rome, Italy
7School of Reproductive and Developmental Medicine, University of Liverpool, Liverpool, United Kingdom
8I.R.C.C.S Multimedica, Scientific and Technology Pole, Milan, Italy

Correspondence to:
Igea D’Agnano, e-mail: igea.dagnano@cnr.it

Keywords: neuroblastoma, TICs, Lamin A/C, MYCN, miRNAs

Received: April 09, 2015  Accepted: August 21, 2015  Published: September 03, 2015

ABSTRACT

Tumor-initiating cells constitute a population within a tumor mass that shares properties with normal stem cells and is considered responsible for therapy failure in many cancers. We have previously demonstrated that knockdown of the nuclear envelope component Lamin A/C in human neuroblastoma cells inhibits retinoic acid-mediated differentiation and results in a more aggressive phenotype. In addition, Lamin A/C is often lost in advanced tumors and changes in the nuclear envelope composition occur during tumor progression. Based on our previous data and considering that Lamin A/C is expressed in differentiated tissues, we hypothesize that the lack of Lamin A/C could predispose cells toward a stem-like phenotype, thus influencing the development of tumor-initiating cells in neuroblastoma. This paper demonstrates that knockdown of Lamin A/C triggers the development of a tumor-initiating cell population with self-renewing features in human neuroblastoma cells. We also demonstrate that the development of TICs is due to an increased expression of MYCN gene and that in neuroblastoma exists an inverse relationship between LMNA and MYCN expression.

INTRODUCTION

Neuroblastoma (NB) is the most common childhood (15% of deaths in children) extracranial tumor of the autonomic nervous system that originates from neural crest-derived sympathoadrenal progenitors. The clinical behavior of NB is correlated with specific genomic abnormalities and high level amplification of the MYCN oncogene [1]. Treatment for patients with advanced disease is aggressive multimodal therapy (e.g. intensive chemotherapy, radiation, surgery, hematopoietic stem cell rescue and immunotherapy) even though the survival of these patients remains at 40–50%.

A reservoir of tumor cells (within a tumor) that has similar properties to normal stem cells might be responsible for therapy failure during long-term remission. This subpopulation of cells has been termed...
cancer stem cells (CSCs) or tumor-initiating cells (TICs). Although hematopoiesis is the most thoroughly studied stem cell system, local resident stem cells could maintain several other organs and many solid tumors, including NB, may contain a population of TICs [2, 3]. However, we know little about the phenotype of NB-TICs. To individuate TICs within a tumor, researchers normally focus on the study of functional stem cell-like characteristics such as self-renewal, tumorigenicity and drug resistance [4].

In a previous paper, we have shown that knockdown of Lamin A/C expression in NB cells inhibits cell differentiation and gives rise to a more aggressive and drug-resistant tumor phenotype [5]. Lamins, which are type V intermediate filaments, are the major components of the nuclear lamina. They are divided into A and B types based on similarities in their primary sequences and biological properties; A- and B-type lamins are expressed in differentiated tissues and ubiquitously, respectively [6, 7]. Additionally, the expression of A-type lamins is often reduced or absent in cells that are highly proliferative, including various malignancies [8, 9]. Based on our previous data and considering the different expression of Lamin A/C during development, we hypothesize that the lack of Lamin A/C could predispose cells toward a more immature phenotype. The aim of the present paper is to investigate whether Lamin A/C expression levels could influence the presence of TICs in NB.

Moreover, we seek to study the mechanism by which Lamin A/C could control tumor aggressiveness in NB. Changes in the composition of the nuclear membrane occur during the progression of several types of cancers [10, 11]. Good functionality of the nuclear membrane could play a crucial role in biological functions such as microRNA (miRNA) processing. miRNA expression is a complex process that requires an initial step of maturation in the nucleus, an intermediate phase of nuclear export, and a final processing of the pre-miRNA into the mature miRNA in the cytoplasm [12]. miRNAs are critical in controlling the self-renewal and differentiation of embryonic stem cells [13] and aberrant expression and/or functions of miRNAs are associated with tumorigenesis and the metastasis in many forms of cancer, including NB [14, 15]. The mechanisms leading to miRNA dysregulation in NB are still not fully understood. Several miRNAs, including the miR-17–92 cluster, are induced by the NB-specific transcription factor MYCN [16–18]. On the other hand, certain miRNAs, such as miR-101, influence MYCN transcription [19].

The data herein demonstrate that knockdown of Lamin A/C triggers the development of a TIC population with self-renewal features in human NB cells.

RESULTS

Abundance of LMNA in NB tumors is inversely correlated with that of MYCN gene

We analyzed the expression levels of the LMNA and MYCN genes in 23 NB biopsies obtained from the Department of Pediatrics and Infantile Neuropsychiatry of Sapienza University. The tumors were classified according to the International Neuroblastoma Pathology Classification (INPC) and staged as stages 1 to 4. Nine of 23 cases showed amplification of MYCN DNA. The expression levels of the two genes significantly inversely correlated (p = 0.01), independently of the DNA amplification of MYCN, in 21 out of the 23 cases analyzed; i.e., as LMNA increased, MYCN gene expression decreased (Fig. 1).

We decided to study this inverse relationship between LMNA and MYCN gene in an in vitro experimental model of NB. We choose the SH-SY5Y and LAN-5 NB cell lines, with N-type morphology. The SH-SY5Y cells express Lamin A/C at high levels and have single copy of MYCN gene [20]; while LAN-5 cells show an amplification of the MYCN gene and do not express Lamin A/C [20]. In particular, since Lamin A/C has been demonstrated to play an epigenetic role in regulating gene expression and miRNAs can be targeted by MYCN, we hypothesized a possible reciprocal regulation between the two genes mediated by miRNAs.

We performed a miRNA expression profiling of LAN5 and SH-SY5Y cells using TaqMan Human MicroRNA Arrays. A total of 768 miRNAs, present in the array, were analyzed in each cell line. The distribution of the expressed miRNAs is shown in a Venn diagram where a total of 417 (66 specific and 351 common) and of 395 (44 specific and 351 common) miRNAs were found expressed in LAN-5 and SH-SY5Y cells, respectively (Fig. 2A). We found 359 and 337 miRNAs not expressed in SH-SY5Y and LAN-5 cells, respectively (293 not expressed at all in both cell lines). We identified a set of 202 out of the 351 common miRNAs differentially expressed at least 2-fold change between the two cell lines (99 in the LAN-5 and 103 in the SH-SY5Y cells); whereas 149 miRNAs were filtered out by the threshold applied. A scatter plot analysis shows the correlation between miRNA expression values (Ct) in LAN-5 and SH-SY5Y cell lines (Fig. 2B). Grey dots distributed along the bisector line represent miRNAs similarly expressed in the two lines (n = 149). While, red or green dots correspond to miRNAs with high expression in the LAN-5 (n = 165) and SH-SY5Y (n = 147), respectively.

Considering the specifically and the differentially expressed miRNAs we performed a functional analysis using the DIANA-mirPath 2.0 tool, and in particular the
software TarBase which uniquely clusters those miRNAs whose targets are experimentally validated [21]. We filtered the clusters obtained based on their significance (FDR corrected $p < 0.05$). As to be expected, target genes resulted grouped into functional categories associated with cancer phenotype. The most modulated miRNAs in both cell lines belong to pathways involved in the regulation of cell proliferation, apoptosis, and response to treatment: “p53 signaling pathway”, “cell cycle”, “pathways in cancer”, “PI3K-Akt signaling pathway”, “transcriptional misregulation in cancer”. These pathways are consistent with the inherent phenotypic characteristics of the two cell lines and correlate to their different capacity to proliferate, to undergo apoptosis, to migrate and invade (Supplementary Table 1). Since a single miRNA can inhibit several target mRNAs and multiple miRNAs can target a single mRNA in a combinatorial fashion, to identify more accurately the differences between

Figure 1: The expression of LMNA and MYCN are inversely correlated in NB human biopsies. qRT-PCR analysis of the LMNA (white) and MYCN (black) genes in 23 NB human biopsies. Data (means + SD [$n = 3$]) are reported as the deltaCt values normalized against the endogenous control. The deltaCt values are inversely correlated with the amount of the gene present in the sample. Statistical significance: $p \leq 0.01$. 

www.impactjournals.com/oncotarget Oncotarget
the miRNome profiles of these two NB cell lines, we intersected the target genes derived from the two cell lines in order to identify the identical genes which were then removed from the analysis. In Table 1 are reported target genes, and relative miRNAs, identified only in SH-SY5Y or LAN-5 cells after removing the identical genes. The gene ontology performed using the DAVID tool on this subset of target genes evidenced that the most relevant enriched functional categories identified in SH-SY5Y cells were associated with cell migration, locomotion and cell proliferation (Fig 2C and Table 2). This indicates that SH-SY5Y cells, which express LMNA gene, have a reduced ability to migrate, to proliferate and hence to be aggressive. Whereas, the LAN-5 cells, which instead express MYCN gene, showed an enrichment in functional categories associated with regulation of differentiation and cell proliferation suggesting that these cells are less prone to differentiate and might show a stem-like phenotype with respect to SH-SY5Y cells (Fig. 2C and Table 2). On the basis of these results, we hypothesize that the mutual expression of MYCN and LMNA genes could address the basis of these results, we hypothesize that the mutual expression of MYCN and LMNA genes could address the phenotypic differences between the two cell lines as concerns tumorigenicity and NB tumor progression, regulation of cell cycle, differentiation and targeting of MYCN. The distribution of the deltaCt values of all the miRNAs studied in 15 tumor tissue specimens resulted very heterogeneous as evidenced in the box plot shown (Fig. 3A). To obtain a more accurate analysis we divided the samples in two groups with high (≤ -1.00) and low (> -1.00) LMNA expression (threshold = LMNA deltaCt median value), including only those specimens whose difference between LMNA and MYCN expression was at least 4-fold (12 out of 15 tumor tissue specimens). Consistent with the changes observed in the two cell lines we found an increased expression of miR-101, miR-34a, miR-424, miR-21, miR-504 and miR-92a which clearly represent the phenotypic differences between the two cell lines as concerns tumorigenicity and NB tumor progression, regulation of cell cycle, differentiation and targeting of MYCN. The distribution of the deltaCt values of all the miRNAs studied in 15 tumor tissue specimens resulted very heterogeneous as evidenced in the box plot shown (Fig. 3A). To obtain a more accurate analysis we divided the samples in two groups with high (≤ -1.00) and low (> -1.00) LMNA expression (threshold = LMNA deltaCt median value), including only those specimens whose difference between LMNA and MYCN expression was at least 4-fold (12 out of 15 tumor tissue specimens). Consistent with the changes observed in the two cell lines we found an increased expression of miR-101, miR-34a, miR-424, miR-21, and a decreased expression of miR-504 and miR-92a in the NB patient group with high LMNA expression compared with the specimen group with low LMNA expression (Fig. 3B).

**LMNA gene knock-down induces a stem-like phenotype in SH-SY5Y cells**

We used as experimental model the SH-SY5Y cells in which we previously inhibited differentiation by LMNA knock-down (LMNA-KD) [5]. First, we analyzed the expression of some stemness-related markers such as NANOG, SOX2, POU5f, PROM-1, CD34 and ABCG2, by qPCR (Fig. 4A). All of these genes were overexpressed in LMNA-KD cells, indicating that lack of the LMNA gene could be associated with a more immature cell phenotype. The activity of ABCG2, which is a member of the ATP-binding cassette (ABC) membrane transporters, and present in many types of stem cells, was also verified evaluating by FACS analysis the exclusion of the fluorescent supravital dye Hoechst 33342 out of the cells. The cells able to pump outside the dye are concentrated in a tailing population exhibiting dim fluorescence relative to the majority of cells with bright fluorescence and they represent the so called “side population”, known to correlate with a stem-like phenotype. Indeed, LMNA-KD cells show the presence of a side population identified by a Hoechst 33342 low-staining fraction (approximately 5%; Fig. 4B). As control to confirm dye efflux and the probable presence of stem-like cells we inhibited the ABCG2 pump by verapamil. Consistently, verapamil treatment led to depletion of this side population in LMNA-KD cells. By contrast, control cells presented the same cytofluorimetric profile in both the presence and absence of verapamil.

We then investigated the ability to form spheres by LMNA-KD cells in the appropriate culture conditions. As a positive control, we used human NB LAN-5 cells, known to form spheres [3]. Similarly to LAN-5 cells, LMNA-KD cells formed secondary spheres in serum-free medium (Fig. 4C). Noteworthy, the mean diameter of the spheres measured in LMNA-KD cells was superimposable to that of the LAN-5 positive control cells (p = 0.18; Fig. 4D). By contrast, control cells did not show any significant capacity to form secondary spheres. We carried out immunofluorescence experiments on the spheres to detect the expression of known stemness markers, such as CD133, SSEA4 and SOX2. LMNA-KD secondary spheres were positive for all the markers considered (Fig. 4E and Supplementary Fig. 1).

**LMNA-KD sphere-derived adherent cells maintain stemness characteristics and acquire a more aggressive phenotype**

Spheres formed from LMNA-KD cells were cultured in adherent conditions for several passages. Sphere-derived adherent cells grew as discrete groups whereas the LMNA-KD cell monolayer showed a dispersed pattern, with growing cells being mainly isolated (Supplementary Fig. 2). We verified the expression of MYCN mRNA levels which significantly increased in LMNA-KD cells and in sphere-derived adherent cells (approximately 2-fold) compared with CTR cells thus confirming our hypothesis (Fig. 5A, left panel). The increased MYCN expression was associated with the down-regulation of the NDRG1 and NDRG2 genes in LMNA-KD cells and in sphere-derived adherent cells (Fig. 5A, right panel). An increase in the N-Myc protein...
Figure 2: Functional analysis of miRNA target genes in LAN-5 and SH-SY5Y cell lines. A. Venn diagram of expressed miRNAs in SH-SY5Y and LAN-5 cells. The number in parenthesis represents the total miRNAs expressed in each line. B. Scatter plot of the miRNA Ct values normalized against endogenous controls in SH-SY5Y and LAN-5 cells. Grey dots represent unchanged miRNAs between the two cell lines; green dots are the SH-SY5Y miRNAs; red dots represent LAN-5 miRNAs. C. Gene ontology by DAVID. In the histogram are reported the number of target genes belonging to the indicated functional categories. Red bar, LAN-5 cells; green bar, SH-SY5Y cells. Statistical significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Table 1: Target genes and relative miRNAs specifically expressed only in SH-SY5Y or LAN-5 cells.

| KEGGterm                                    | Count | P Value | Genes                        | Count | miRNA [TarBase]          |
|----------------------------------------------|-------|---------|------------------------------|-------|--------------------------|
| hsa04115:p53 signaling pathway              | 22    | 1.08E-29| APAF1 CASP8 SESN1 MDM4 CDKN2A TP73 | 18    | miR-101-3p miR-26b-5p miR-21-5p |
|                                             |       |         | ATM CCND3 SFN PIDD1 DDB2 ZMAT3 |       | miR-424-5p miR-93-5p miR-193a-5p |
|                                             |       |         | BID CCNE1 THBS1 RFWD2 EI24 GADD45A |       | miR-34a-5p miR-24-3p miR-374a-5p |
|                                             |       |         | CASP3 CCNG2 TP5313 SERPINB5 |       |                            |
| hsa05200:Pathways in cancer                 | 51    | 5.47E-24| APPL1 CCNE1 FGF1 ITGA6 MMP2 TP53 | 36    | miR-214-3p let-7c miR-222-3p |
|                                             |       |         | AR CHUK FGFR1 JUN MMP9 BMP2 |       |                            |
|                                             |       |         | AXIN2 CRKL FZD4 LAMC2 NFKB1A ERBB2 |       |                            |
|                                             |       |         | BID DAPK1 HDAC1 MAP2K1 NRAS IKBKB |       | miR-146b-3p miR-93-5p miR-503 |
|                                             |       |         | PLD1 STAT1 VHL RALA TCF4 MMP1 |       |                            |
|                                             |       |         | PTK2 STAT5A WNT1 RALB TFG PIK3R1 |       |                            |
|                                             |       |         | RB1 TGFB2 RUNX1 TGFB1 SKP2 PDGFB |       |                            |
|                                             |       |         | BIRC3 DVL2 HSP90AA1 MAPK1 PDGFA MAPK9 |       |                            |
|                                             |       |         | BIRC5 E2F3 IGF1R |       |                            |
| hsa04110:Cell cycle                         | 17    | 6.56E-21| ANAPC13 ATM CCND3 CCNE1 CDC14A GADD45A | 14    | miR-424-5p miR-34a-5p let7d-5p |
|                                             |       |         | MDM2 ORC4 SFN SKP2 TP53 HDAC1 |       |                            |
|                                             |       |         | CDC23 CDC25C E2F3 E2F5 EP300 |       | miR-374a-5p let-7c miR-25-3p |
|                                             |       |         | PDGFA MAP2K2 IGF1R FGFR1 |       |                            |
|                                             |       |         | PDGFB MDM2 IKBKB FGFR3 COL4A1 CCNE1 |       |                            |
|                                             |       |         | PDGFAC MYB INSR GNG5 COL5A3 CDC37 |       |                            |
|                                             |       |         | PIK3CB NRAS IRS1 HSP90AA1 EIF4E CHUK |       |                            |
| hsa04110:PI3K-Akt signaling pathway         | 32    | 1.02E-07| PDGFA MAP2K2 IGF1R FGFR1 COL3A1 CASP9 | 26    | let-7c miR-449a miR-100-5p |
|                                             |       |         | PDGFB MDM2 IKBKB FGFR3 COL4A1 CCNE1 |       |                            |
|                                             |       |         | PDGFAC MYB INSR GNG5 COL5A3 CDC37 |       |                            |
|                                             |       |         | PIK3CB NRAS IRS1 HSP90AA1 EIF4E CHUK |       |                            |

(Continued)
### SH-SY5Y

| KEGGterm | Count | P Value | Genes | Count | miRNA|TarBase |
|----------|-------|---------|-------|-------|------|---------|
| hsa05202: Transcriptional misregulation in cancer | 39 | 3.14E-03 | PPP2R1B PAK1 MAP2K1 IFNB1 FGF1 COL1A1 | miR-26a-5p miR-34b-5p |
|         | 19 |         | TGFBR2 PDGFB MEIS1 Il6 HIST2H3C HIST1H3H | miR-34a-5p miR-223-3p miR-363-3p |
|         |     |         | TP53 RUNX1 MYC KLF3 HIST3H3 HIST1H3I | miR-146b-3p miR-93-5p miR-25-3p |
|         |     |         | ZEB1 SMAD1 MYCN LMO2 HOXA9 HIST1H3J | miR-27a-3p miR-26a-5p miR-101-3p |
|         |     |         | SP1 PAX3 MEF2C IGF1R HIST2H3A HIST1H3E | miR-28-5p |
|         |     |         | HIST1H3C H3F3B CEBPB BIRC3 CDKN2C BAIAP3 |     |
|         |     |         | HDAC1 FOXO1 CCND2 ATM HIST1H3B H3F3A |     |
|         |     |         | HIST1H3A GOLPH3 CDKN1B |     |

### LAN-5

| KEGGterm | Count | P Value | Genes | Count | miRNA|TarBase |
|----------|-------|---------|-------|-------|------|---------|
| hsa04110:Cell cycle | 6 | 4.05E-32 | BUB1B ORC6 PKMYT1 SMAD3 SMAD2 | miR-155-5p miR-193b-3p |
|         |     |         | PRKDC |     |      |         |
| hsa05200: Pathways in cancer | 21 | 1.12E-08 | RAC2 RAD51 TCF7L1 NFKB2 SMAD2 | miR-155-5p miR-378a-5p |
|         |     |         | CDH1 FN1 SUFU RHOA RAC2 | miR-193b-3p miR-200c-3p |
|         |     |         | HSP90AB1 CASP9 MAX NKX3-1 FGF7 | miR-504 |
|         |     |         | CTNNA1 JUP SMAD3 FGF2 CDK2 |     |
|         |     |         | BAX |     |      |         |
| hsa04115: p53 signaling pathway | 2 | 1.35E-05 | BAX RCHY1 | miR-504 miR-19a-3p |
| hsa04110: PI3K-Akt signaling pathway | 15 | 8.07E-03 | EIF4E2 FGF2 FGF7 FLT1 GNB4 | miR-155-5p miR-19a-3p |
|         |     |         | ITGB4 ITGB5 RHEB PKN2 PRK CZ |     |
|         |     |         | THBS1 YWHAZ NFKB1 PCK2 PDK1 |     |
| hsa05202: Transcriptional misregulation in cancer | 2 | 4.32E-02 | CD40 BCL2L1 | miR-486-5p miR-491-5p |
accompanied the increase in MYCN gene expression in LMNA-KD cells and sphere-derived adherent cells, as evaluated by FACS analysis (approximately 40 and 65%, respectively; Fig. 5B).

We characterized the LMNA–KD sphere-derived adherent cells to evaluate the mRNA expression levels of self-renewal genes compared to those in the control cell line. The stemness marker genes maintained their expression or were further up-regulated in LMNA-KD sphere-derived adherent cells (Fig. 5C). In particular, we observed a strong up-regulation of the stemness network of the transcription factor genes NANOG, POU5f and SOX2 and of the drug resistance-related gene ABCG2. In addition, sphere-derived adherent cells maintained their self-renewal ability, as they were still able to form cell spheres in non-adherent culture conditions.

We used murine embryonic stem cells (mES) to study the expression of Lamin A/C protein in a pluripotent stem cell model. mES, cultured in stemness conditions, homogeneously showed the presence of OCT4 (data not shown). When Leukemia inhibitory factor (LIF, an interleukin 6 class cytokine that affects cell growth by

Table 2: Gene Ontology analysis on the target genes specifically expressed only in SH-SY5Y or LAN-5.

| GOTERM                                      | P value | Count | Target Genes                                                                 |
|----------------------------------------------|---------|-------|-------------------------------------------------------------------------------|
| GO:0051094–positive regulation of developmental process | 9.707E-05 | 7     | BAX, RHOA, SMAD3, NFKB1, SMAD2                                                |
|                                             |         |       | THBS1, FGF2                                                                  |
| GO:0001952–regulation of cell-matrix adhesion | 0.002   | 3     | PRKCZ, SMAD3, THBS1                                                           |
| GO:0008285–negative regulation of cell proliferation | 0.003   | 6     | BAX, NKX3-1, SMAD3, SMAD2, THBS1                                              |
|                                             |         |       | FGF2                                                                         |
| GO:0045597–positive regulation of cell differentiation | 0.004   | 5     | RHOA, SMAD3, NFKB1, SMAD2, FGF2                                              |

| GOTERM                                      | P value | Count | Genes                          |
|----------------------------------------------|---------|-------|--------------------------------|
| GO:0051726–regulation of cell cycle          | 4.84E-16 | 25    | STAT5A, SFN, CCNG2, CDC37, TGFB2 |
|                                             |         |       | CASP3, CDKN2A, CDKN2C, INSR, MYC   |
|                                             |         |       | BMP2, TP53, SKP2, CDC23, BIRC5     |
|                                             |         |       | RB1, CDC25C, ATM, CDKN1B, HDAC1   |
|                                             |         |       | CCND3, CCND2, JUN, MDM2, GADD45A |
| GO:0030335–positive regulation of cell migration | 1.21E-11 | 13    | IL6, PLD1, PDGFB, MAP2K1, PDGFA   |
|                                             |         |       | MMP9, IRS1, TGFB2, IGF1R, MAPK1   |
|                                             |         |       | THBS1, INSR, PIK3R1               |
| GO:0007049–cell cycle                       | 5.21E-11 | 29    | E2F3, CDC14A, ANAPC13, SESN1, CCNG2 |
|                                             |         |       | TGFB2, CCNE1, CDKN2A, CDKN2C, THBS1 |
|                                             |         |       | MYC, MAP2K1, TP53, SKP2, CDC23    |
|                                             |         |       | BIRC5, RB1, CDC25C, APPL1, ATM    |
|                                             |         |       | TP73, MAPK1, CDKN1B, EP300, CCND3 |
| GO:0001952–regulation of cell-matrix adhesion | 0.002   | 4     | CDKN2A, PIK3CB, THBS1, PIK3R1    |
| GO:0007626–locomotory behavior              | 0.003   | 9     | MAPK1, PLD1, IL6, MAP2K1, PDGFB   |
|                                             |         |       | PDGFA, PIK3CB, RALA, TGFB2       |

| GOTERM                                      | P value | Count | Genes                          |
|----------------------------------------------|---------|-------|--------------------------------|
| GO:0051094–positive regulation of developmental process | 9.707E-05 | 7     | BAX, RHOA, SMAD3, NFKB1, SMAD2 |
|                                             |         |       | THBS1, FGF2                                                                  |
| GO:0001952–regulation of cell-matrix adhesion | 0.002   | 3     | PRKCZ, SMAD3, THBS1                                                           |
| GO:0008285–negative regulation of cell proliferation | 0.003   | 6     | BAX, NKX3-1, SMAD3, SMAD2, THBS1                                              |
|                                             |         |       | FGF2                                                                         |
| GO:0045597–positive regulation of cell differentiation | 0.004   | 5     | RHOA, SMAD3, NFKB1, SMAD2, FGF2                                              |
Figure 3: miRNA validation in NB human biopsies. A. Boxplot diagrams of deltaCt values of the indicated miRNAs. Each box represents the distribution of the deltaCt measured for a single miRNA in 15 tumor tissue specimens. Bottoms and tops of the boxes define the 25th and 75th percentile, the band inside the box defines the median, and the ends of the whiskers define the lowest and the highest value of all data. B. Data are expressed as percentage variation (+SD) of the indicated miRNAs in the NB patient group with high LMNA expression compared with the specimen group with low LMNA expression, defining high and low LMNA expression on the LMNA deltaCt median values (threshold = -1.00) ($p = 0.008$).
Figure 4: SH-SY5Y LMNA-KD cells acquire stemness characteristics. A. qRT-PCR analysis of the indicated genes in control (CTR; white) and LMNA-KD (black) cells. The data are reported as the level of mRNA relative to the number of control cells and are the means+SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01. B. Flow cytometric analysis of side population after staining with Hoechst 33342 in the absence or presence of verapamil to inhibit the functionality of the membrane ABCG2 efflux pump. C. Tumor sphere assay of LMNA-KD cells compared to control and LAN-5 cells; phase contrast micrographs of the secondary spheres, magnification 200X. D. Mean diameter (+SD) of the secondary spheres formed in LMNA-KD cells and compared with those obtained in LAN-5 cells (p = 0.18). The SH-SY5Y cells did not produce any measurable spheres but only aggregates. E. Representative confocal images of the secondary tumor spheres. CD133 immunostaining (red) and nuclear staining (blue). Scale bar: 50 μm.
Figure 5: LMNA–KD sphere-derived adherent cells possess self-renewal and tumor progression characteristics.

A. RT-qPCR analysis of MYCN mRNA levels (right panel) and of NDRG1 and NDRG2 mRNA levels (left panel) in CTR cells (white), LMNA-KD cells (grey) and LMNA–KD sphere-derived adherent cells (black). The data are reported as the level of mRNA relative to CTR cells and are the means±SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. B. FACS analysis of N-Myc expression in control and LMNA-KD cells. LAN-5 cells were used as a positive control. The number reported in each histogram represents the percent positivity.

C. RT-qPCR analysis of the indicated genes in CTR cells (white), LMNA-KD cells (grey) and the sphere-derived adherent cell line (black). The data are reported as the level of mRNA relative to LMNA-KD cells and are the means±SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. D. Representative immunofluorescence for Oct4 (red fluorescence) on mES culture, 4 days after exposure to growth medium lacking LIF interleukin, attesting the pluripotency of the cells. The absence of a signal for Oct4 and the presence of Lamin A/C (green fluorescence) demonstrate the lack of pluripotency and the beginning of the differentiation process. Nuclei were stained with DAPI (blue fluorescence). Scale bars: 20 μm. E. Relative expression of tumor aggressiveness-related genes in CTR cells (white), LMNA-KD cells (grey) and the sphere-derived adherent cell line (black). The data are reported as the level of mRNA relative to LMNA-KD cells and are the means±SD (n = 5). Statistical significance: **p ≤ 0.01, ***p ≤ 0.001.
inhibiting differentiation) was removed from the culture medium, allowing a generic differentiation, we detected the presence of Lamin A/C in those cells that did not express OCT4 anymore, suggesting that Lamin A/C could be an exclusive characteristic of the cells that begin the differentiation process (Fig. 5D).

Sphere-derived adherent cells appeared to acquire a more aggressive phenotype than LMNA-KD cells (Fig. 5E). The ENPP2 metastasis-associated gene showed a 4-fold increase with respect to LMNA-KD cells. In addition, the EDN1 and CD44 genes, known to be involved in cell adhesion functions, significantly decreased in the sphere-derived adherent cell line.

Mainly, these data strongly suggest that LMNA-KD sphere-derived adherent cells possess self-renewal and tumor progression characteristics that are peculiar of a putative population of tumor-initiating cells (TIC-like cells).

The LMNA-KD sphere-derived adherent cell line is able to initiate tumors in vivo

We performed a limiting dilution assay in LMNA-KD sphere-derived adherent cells (namely TIC-like cells in this paper) to determine the minimum cell dilution capable of forming colonies in vitro. While TIC-like cells maintained colony forming ability at very low dilution (down to 16 cells), LMNA-KD cells did not form colonies at such dilution (Fig. 6A).

On this basis, we compared the in vivo growth of the two cell lines using an in vivo limiting dilution assay. Immunosuppressed mice were injected subcutaneously with different number of LMNA-KD and TIC-like cells (from $5 \times 10^4$ to $1 \times 10^7$). No differences in terms of tumor appearance and tumor growth were evident injecting from $2.5 \times 10^5$ to $1 \times 10^7$ TIC-like and LMNA-KD cells (data not shown). While, at lower number, TIC-like cells exhibited a higher growth rate than LMNA-KD cells (Fig. 6B); this was evident when mice were injected with $10^5$ cells (left panel), but a more marked difference between TIC-like and LMNA-KD cells was found in terms of tumor mass when $5 \times 10^4$ cells were injected per mouse (right panel). In fact, a significant increase in the weight of the TIC-like-derived tumors compared to the LMNA-KD-derived tumors (an almost doubling) was observed as the maximum effect (on day 14 after tumor cell injection) ($p = 0.003$). A significant difference between the two tumor growth rate was maintained also at day 21 and 28 after tumor cell injection ($p = 0.01$).

The histopathological pattern of these tumors, analyzed on day 27 of tumor growth, showed small cells with round to oval shapes, deeply stained nuclei and poorly defined cytoplasmic outlines. Unlike LMNA-KD-derived tumors, TIC-derived tumors were mainly microscopically characterized by a nodular pattern of growth. Small aggregates with mostly hyperchromatic nuclei were defined by the presence of fibrous septa. We also observed hypercellularity and overlapping nuclei occasionally exhibiting small nucleoli in TIC-derived tumors. These findings further demonstrate the more malignant phenotype of TIC tumors (Fig. 6C).

MYCN expression is increased by miR-101 inhibitor in SH-SY5Y NB cells

From a more accurate analysis of the table 1 we found that MYCN gene appeared as one of the miRNA target in the SH-SY5Y cells, whereas LMNA did not emerge as a miRNA-regulated gene in the LAN-5 cells, thus indicating that the absence of MYCN expression in SH-SY5Y cell line might be the results of miRNA regulation. Since miR-101 is a specific miRNA known to target also MYCN gene [19, 22], we inhibited miR-101 in SH-SY5Y control cells to modulate MYCN expression. As control, we overexpressed miR-101 in LMNA-KD cells in order to verify the effect on MYCN gene expression. As expected, the analysis of the intrinsic expression of miR-101 in both cell lines, revealed miR-101 less expressed in LMNA-KD cells by 50% compared to SH-SY5Y control cells (Fig. 7A).

Transfection of SH-SY5Y control cells with the miR-101 inhibitor decreased the expression levels of miR-101 by approximately 50% (Fig. 7B, left panel). Transfection of LMNA-KD cells with the miR-101 mimic resulted in approximately 90-fold increased expression of miR-101 (Fig. 7B, right panel). The analysis of the MYCN transcripts resulted significantly increased or decreased after transduction of miR-101 inhibitor or mimic, respectively (Fig. 7C). We then analyzed the mRNA levels of genes involved in some of the MYCN-regulated pathways such as stemness and aggressiveness. The expression of the same genes up-regulated in SH-SY5Y control cells after the inhibition of miR-101, decreased in LMNA-KD cells after the overexpression of miR-101. Consistently, after inhibiting miR-101, SH-SY5Y control cells showed down-regulation of the tumor suppressor EDN1 and CD44 genes, and increased expression of the tumor progression ENPP2 gene with respect to LMNA-KD cells transfected with the miR-101 mimic (Fig. 7C). We also verified the effect of the N-Myc transcription factor on the LMNA gene expression by analyzing the expression of LMNA gene in SH-SY5Y in which we overexpressed MYCN either by inhibiting miR-101 or by ectopically transducing a MYCN construct. In both cases we did not observe any increase in the expression of the LMNA gene and of the Lamin A/C protein (data not shown).

DISCUSSION

This paper demonstrates that the down regulation of Lamin A/C expression in the SH-SY5Y NB cells allows the development of a tumor-initiating cell (TIC)
Figure 6: The LMNA-KD sphere-derived adherent cell line is able to initiate tumor growth in vivo. A. In vitro plating efficiency (PE %) in LMNA-KD (white) and sphere-derived adherent (black) cells at different cell dilutions. B. LMNA-KD (•) or sphere-derived adherent (○) cells were injected subcutaneously into the flanks of immunosuppressed mice at $10^5$ (left panel) or $5 \times 10^4$ (right panel) cells/mouse in 200 μl of Matrigel. When a tumor mass was evident, the tumor sizes were measured, and the tumor weight was calculated using the following formula: $a \times b^2/2$, where $a$ and $b$ are the long and short diameters of the tumor, respectively. The mean ± SD tumor weights are reported ($p = 0.003$, at day 14 and $p = 0.01$ at day 21 and 28 after tumor cell injection). C. Histopathological examination of tumor biopsies from LMNA-KD cells and TICs after 27 days of tumor growth. Images shown are at 20X (left panels) and 40X (right panels) magnification.
**Figure 7:** Modulation of hsa-miR-101 modifies the expression of MYCN gene and in turn of stemness and cancer-related genes.

**A.** TaqMan MicroRNA Assay with hsa-miR-101 in CTR cells (white) and LMNA-KD cells (black). The data are reported as the level of mature miRNA and mRNA relative to CTR cells and are the means±SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01.

**B.** TaqMan MicroRNA Assay, with the hsa-miR-101 levels in CTR cells transfected with the inhibitor (white, left panel) or in LMNA-KD cells transfected with the mimic (black, right panel). The data are reported as the level of mature miRNA compared to each relative negative control and are the means±SD (n = 5). Statistical significance: ***p ≤ 0.001.

**C.** qRT-PCR analysis of the indicated genes in hsa-miR-101 mimic-transfected LMNA-KD cells (black) and hsa-miR-101 inhibitor-transfected CTR cells (white). The data are reported as the level of mRNA compared to each relative negative control and are the means±SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
population with self-renewal features and the ability to initiate tumors in vivo.

TICs have been identified in many tumor types as a small tumorigenic population of cells that are responsible for sustaining tumor growth and metastatic spread, thus representing the cause of cancer recurrence [23–25]. Their presence has been demonstrated in the bone marrow of patients with relapsed NB [2], and they have many stem cell characteristics, such as sphere-forming ability and self-renewal. However, sphere-forming ability is not a general characteristic of NB tumor-derived cell lines, as reported by Mahller and colleagues [3], who studied the capacity to give rise to spheres in eight NB cell lines, including SH-SY5Y. In accordance with these authors, we also found that NB SH-SY5Y cells were not able to form spheres. However, when we silenced the LMNA gene in these cells, they gave rise to spheres in serum-free culture conditions that were optimized for neural stem cell growth. The capacity to form spheres clearly demonstrates that this selected population possesses the self-renewal characteristics of a stem cell phenotype. Pluripotency is a unique state in which cells can self-renew indefinitely while maintaining the ability to differentiate. The mechanism that controls the transcription of core pluripotency factors has been extensively studied [26, 27]. In normal embryonic stem cells, the gene regulatory networks of the core transcription factors Oct4, Nanog and Sox2 are involved in pluripotency maintenance [27]. Consistently, we found that the three main genes belonging to the stem cell regulatory network (POU5f, which encodes Oct4, NANOG and SOX2) were all significantly overexpressed in LMNA-KD-derived tumor spheres and even more so when the sphere cell population was cultured as adherent cells.

In addition, the fact that these spheres are highly positive for the CD133, SOX2 and SSEA4 markers further supports the stem-like phenotype of LMNA-KD cells. We also found in LMNA-KD-derived tumor spheres a marked increase in the expression of the ABC membrane transporter gene ABCG2. Increased expression of this gene is considered a major characteristic of the cancer stem cell population that is associated with different tumor types [28]. The increased expression of this drug resistance-related gene often correlates with the presence of a side population [29]. Indeed, we found the unambiguous presence of a side population completely abolished by the exposure to verapamil, a known inhibitor of the membrane drug efflux-pump, in LMNA-KD cells.

To further corroborate that this cell population with self-renewal characteristics was a TIC population, we studied the capacity of these cells to give rise to tumors. The analysis of tumor growth in vivo clearly demonstrated that the putative TICs were more markedly aggressive, as evidenced by their significant higher growth rate at low cell concentrations than the LMNA-KD whole cell population and by the more malignant phenotype of the tumor tissues. It is likely that the enhanced tumorigenicity of TICs may depend on their maintenance in supportive micro-environmental “niche”. In normal tissues a “niche” consists of a microenvironment formed by cellular and non-cellular components which together are able of housing and maintaining stem cell homeostasis. On the other hand, there is evidence that the normal cells that surround and infiltrate tumors secrete factors that promote the growth and progression of cancer. Vermeulen et al. [30] reported that the microenvironment was imperative for regulating functional activity associated to colon TICs. Similarly, Calabrese et al. [31] demonstrated that brain vascular niche is responsible for promoting self-renewal and accelerating tumor growth from brain TICs. As reported by others in different tumor types including neuroblastoma [2, 32] we also used Matrigel in our in vivo studies in order to provide to TICs a complete microenvironment and biological substrates to promote TIC xenograft tumor formation.

The aggressiveness of the TIC population was also evidenced by increase of ENPP2 and decrease of EDN1 and CD44 gene expression. We can therefore conclude that the LMNA-KD sphere-derived cells represent a TIC population.

The inverse relationship between LMNA and the NB marker MYCN found in the TICs indicate that these two genes could mutually regulate differentiation and stemness in NB. Indeed, TICs which express more MYCN than SH-SY5Y control cells and are silenced for LMNA gene, also show a significant increase of the NANOG, POU5f and SOX2 gene expression. This is supported by the data obtained from biopsies of human NB. Indeed, we found, for the first time in this paper, a defined inverse relationship between LMNA and MYCN gene expression in 23 human NB biopsies.

On the other hand, the miRNome analysis in two NB cellular model expressing LMNA or MYCN alternatively, evidenced changes of members of miRNA signatures which control cell proliferation and differentiation. In fact, in the SH-SY5Y LMNA expressing cells DAVID pathway analysis revealed that the miRNA target genes belonged mainly to pathways related to cell cycle regulation indicating that the expression of Lamin A/C is associated with a more mature phenotype. This confirm data of a previous paper from our laboratory where we demonstrated that LMNA knock-down inhibit differentiation processes. By the contrary, in the LAN-5 MYCN expressing cells the miRNA target genes identified belonged to pathways related to the inhibition of the developmental processes. In particular, some of these genes (SMAD2/3, FGF2) appear to be involved in stem cell differentiation processes [33, 34]. The very different number of miRNAs identified in each cluster comparing the two cell lines support our hypothesis. It is likely that miRNAs and their target genes in LAN-5 cells tend to display a low number of clusters as a consequence of reduced number of pathways to be regulated to maintain their stem-like
phenotype. By contrast, SH-SY5Y cells need to control a higher number of pathways than LAN-5 cells, due to their more mature phenotype. On the other hand, it is important to highlight that the analysis has been performed considering uniquely validated target. The validation in NB human specimens of some of the relevant miRNAs differentially expressed in the two NB cell lines confirms in the tumor biopsies the expression profiles obtained in the two cell lines. This suggests that this group of miRNAs could be the basis for a further identification of a miRNA signature representative of tumor progression in relation to LMNA expression.

The MYCN crucial role in the control of tumor initiating cell development is further demonstrated by data obtained modulating MYCN expression through miR-mediated regulation. The choice to modulate MYCN by miR-101 mediated regulation is based on the analysis of the miRNA array performed in SH-SY5Y and LAN-5 cells (see supplementary table 1). We evidenced hsa-miR-101–3p and hsa-miR-34a-5p as specific miRNAs targeting MYCN gene [19]. To confirm that these miRNAs were expressed at higher levels in SH-SY5Y than in LAN-5 cells we performed a qRT-PCR which confirmed the array result (data not shown). In addition, only miR-101 expression was decreased in LMNA-KD compared to control cells; while the expression of miR-34a did not change (data not shown). This suggests that only the former miRNA could have a role in regulating MYCN mRNA after LMNA knock-down. In fact, up-regulating MYCN in SH-SY5Y control cells, they acquired a stem-like phenotype; while down-regulating MYCN in LMNA-KD cells, we were able to restore a more mature phenotype. On the other hand, overexpression of the MYCN gene correlates with increased stemness characteristics [35–37]. In addition, the role of the MYCN gene in promoting tumor invasion, particularly in NB cells, is well known [38–40]. However, LMNA gene expression did not change when we increased MYCN in SH-SY5Y cells, indicating that an inverse correlation between LMNA and MYCN does not exist. Moreover, an in silico analysis of the LMNA promoter did not evidenced the presence of the Myc family transcription factors peculiar consensus sequence.

Our data provide new mechanistic insight into the development of a stem-like NB TIC population. In a tumor-mass, TICs constitute a rare tumorigenic cell population responsible for sustaining tumor growth, metastases and relapse. Our data may provide opportunities to develop new personalized therapeutic strategies based on the molecular profile of the tumor.

MATERIALS AND METHODS

Human NB biopsy RNA extraction and real-time RT-PCR

Total RNA was extracted from twenty-three frozen biopsies of human newly diagnosed NBs obtained from Department of Pediatrics and Infantile Neuropsychiatry of Sapienza University, Rome using TRIzol reagent (Life Technologies) according to the manufacturer’s instructions. RNA was reverse-transcribed, and real-time PCR performed as described below. The amplification efficiencies of the primers for MYCN and LMNA genes were tested and resulted identical (LMNA efficiency = 2.1; MYCN efficiency = 2.0). Institutional written informed consent was obtained from the patient’s parents or legal guardians according to the local institutional guidelines.

Cell line maintenance and sphere formation

The SH-SY5Y NB cell line was purchased from ATCC. In this study, we also used two SH-SY5Y-derived clones, LMNA-KD and control (CTR) cells that were grown as previously described [5]. The LAN-5 NB cell line (a gift from Dr. Doriana Fruci) was grown in RPMI-1640 medium (Gibco) supplemented with 10% FBS (Hyclone), 2 mM L-glutamine and 1% penicillin/streptomycin in a fully humidified incubator containing 5% CO2 at 37°C. To obtain spheres, cells were plated in a serum-free media in 60-mm, low-attachment culture dishes at a density of 9.5 × 103 cells/cm2 and cultured in Neurobasal Medium (Gibco) supplemented with 20 ng/ml Epidermal Growth Factor (EGF, Sigma), 40 ng/ml basic Fibroblast Growth Factor (bFGF, Sigma), 1% neuronal supplement N2 (Gibco) and B27 (Gibco), and 2 µg/ml heparin. Three days after seeding, the cells formed floating neurosphere-like structures that grew rapidly until day 7. Before these structures became necrotic, we harvested and suspended them in Accutase enzymatic solution (Gibco) for 5 min at 37°C and then mechanically dissociated into a single-cell suspension. The cells were re-seeded in the same conditions as above, and the secondary spheres were allowed to form. As positive and negative controls, we used NB LAN-5 and SH-SY5Y cell lines, respectively. The secondary spheres were measured using ImageJ software and the value of diameter expressed in μm. TICs were derived by harvesting the secondary spheres, treating them with Accutase enzymatic solution (Gibco) for 5 min at 37°C and then mechanically dissociating them into a single-cell suspension. These cells were seeded in adherent conditions in the presence of 1:1 mixture of Eagle’s Minimum Essential Medium and F12 medium (Gibco) supplemented with 10% FBS (Hyclone), 2 mM L-glutamine, 0.5% non-essential amino acids, 0.5% sodium pyruvate and 1% penicillin and streptomycin. mES cells were cultured following the protocol provided by ATCC (ES-D3, CRL-1934 ATCC).

Total RNA preparation

Total RNA was isolated using a Total RNA purification kit (Norgen Biotek). RNA quantity was determined by measuring absorbance at 260 nm using a NanoDrop UV-VIS spectrophotometer. The quality
and integrity of each sample was confirmed using a BioAnalyzer 2100 (Agilent RNA 6000 Nanokit); samples with an RNA Integrity Number (RIN) index lower than 8.0 were discarded.

**PCR array**

RNA was reverse transcribed using TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems), cDNA was preamplified using TaqMan PreAmp Master Mix (Applied Biosystems). qRT-PCR was performed with an Applied Biosystem 7900HT thermal cycler using TaqMan human microRNA array (TaqMan Human microRNA Array A #4398977 and B v3.0 #442812; Applied Biosystems) according to manufacturer’s instructions. The downstream analysis filtered out miRNAs not detected in both cell lines (293), whereas those specifically expressed either in LAN-5 or in SH-SY5Y were considered and reported as cell line-specific. Data were then normalized calculating the ∆Ct value for single miRNA against the average of the specific controls for each card according to manufacturer’s instructions. Differential expression analysis was performed according to ∆∆Ct method and only RQ ≥ 2 fold-change were considered for further analysis. miRNAs clusters were generated through the DIANA web tool mirPath v2.0 using miRBase MIMAT IDs (Release 21) remapped to the newest human genome assembly (GRCh38) to avoid duplicate entries present in the previous release. Uniquely targets reported in TarBase database v7.0 were included in the clustering, predicted targets were not taken into account. False Discovery Rate (FDR) correction was applied to the original p-value and only clusters with corrected p-values < 0.05 were shown.

**Real-time RT-PCR analysis**

RNA was reverse-transcribed and real time PCR analysis were performed as previously described [41]. The specific primers used (each at a concentration of 200 nM) are reported in Supplementary Table 2. Each experiment was performed in triplicate. The expression data were normalized using the Ct values of GAPDH and TBP.

**Side population**

To analyze the side population phenotype, LMNA-KD cells were stained according to the protocol of Goodell et al. [42]. Briefly, 5.0 × 10⁶ cells/ml were suspended in pre-warmed DMEM. Hoechst 33342 (Sigma) was added at a final concentration of 5 μg/ml in the presence or absence of 50 μM verapamil (Sigma), and the cell samples were incubated for 90 min at 37°C with intermittent shaking. After incubation, the cells were washed with ice-cold PBS, resuspended in ice-cold PBS, and analyzed for Hoechst 33342 efflux with a FACS Aria II (Becton Dickinson). The Hoechst 33342 dye was excited at 375 nm, which is near-ultraviolet, and the resultant fluorescence was measured at two wavelengths, using 450/40 BP and 670 LP filters for the detection of Hoechst blue and red, respectively. All data were analyzed using the Diva 6.1 Software (Becton Dickinson).

**Tumor sphere CD133 immunofluorescence**

Spheres were cultured as previously described, harvested and then allowed to spontaneously settle in a 50-mL polystyrene conical tube. Excess supernatant was removed. Spheres were dispensed in an 8-well μ-Slide (Ibidi) and allowed to settle, and Matrigel from a 5X Matrigel BME Coating Solution (Trevigen) was added to 0.1X. The cells were fixed in ice-cold methanol for 20 min and permeabilized in 0.5% Triton X-100 containing 0.3% serum for 10 min. Blocking was carried out in Tris-buffered saline (TBS) solution with serum (1:5) for 10 min. The primary antibody anti-CD133 (clone 293C3; Miltenyi Biotec) was diluted in the blocking solution with 0.5% Tween-20, and the spheres were incubated overnight. The cells were washed three times in TBS and incubated with goat anti-mouse Alexa 594 F(ab)2 (in TBS plus 0.5% Tween-20). After three washes in TBS, the nuclei were stained with Hoechst 33342 Images were acquired using a confocal laser scanning microscope (Leica Confocal Microsystem TCS SP5). The images were processed using Leica Application Suite 6000, the brightness and contrast of the acquired images were adjusted, and the figures were generated using Adobe Photoshop 7.0.

**Immunocytochemistry in murine ES**

mES were fixed in 4% paraformaldehyde for 10 minutes and incubated overnight at 4°C with the following primary antibodies used at 1:100: mouse monoclonal anti-Oct4 (OCT4; BD) and goat anti-Lamin A/C (JOL2; Chemicon Int.). After three washes with PBS, the cells were incubated with a 1:100 dilution of fluorescent-conjugated secondary antibodies for 1 h at room temperature. Secondary antibodies were: donkey anti-mouse IgG Alexa-Fluor 555 (Jackson ImmunoResearch) and donkey anti-goat IgG Alexa-Fluor 488 (Jackson ImmunoinResearch). Negative controls were tested by incubation of only the secondary antibody without a primary antibody incubation: all secondary antibodies were negative for non-specific staining. After three washes, the sections were mounted with VECTASHIELD (Vector Laboratories) plus DAPI.

**N-Myc FACS analysis**

SH-SY5Y CTR, LMNA-KD cells and TICs were analyzed by indirect immunofluorescence. The cells were harvested, washed in cold 1X PBS and fixed (1 × 10⁶ cells/ml) in a solution containing cold acetone/methanol (1:4 v/v) in 50% 1X PBS. For each
sample, $1 \times 10^6$ cells were incubated with the human monoclonal antibody anti-N-Myc (Santa Cruz) in medium containing 10% FBS and 0.5% Tween 20 for 1 h at room temperature. After washing in PBS, the cells were incubated with FITC-conjugated goat anti-mouse IgG (BD, Pharmingen) in PBS for 50 min. After an additional wash in PBS, the samples were measured using a FACSCalibur cytometer (Becton Dickinson). Samples incubated with IgG isotype control antibody were used as negative controls, and NB LAN-5 cells were used as a positive control. The analysis was performed using the CellQuest software package. To determine the N-Myc immunofluorescence positivity we used the method of 2% of background.

**Colony-forming assay**

The LMNA-KD and sphere-derived adherent cell line were seeded at decreasing clonal densities (range: 15–1,000 cells/dish) in 60-mm Petri dishes. Fifteen days after seeding, the cells were fixed for 10 min in ice-cold methanol. A solution of 0.5% crystal violet in 25% methanol was added to the monolayer for 30 min. The dishes were then washed with ddH2O, and the colonies (at least 50 cells) were counted. The results were expressed as plating efficiency (percentage of colonies formed from the number cells seeded).

**In vivo experiments**

Six- to eight-week-old CD-1 male nude (nu/nu) mice weighing 22–24 g were purchased from Charles River Laboratories (Calco, Italy). The procedures involving mouse care were in compliance with the Regina Elena National Cancer Institute animal care guidelines and with international directives (directive 2010/63/EU of the European parliament and council; Guide for the Care and Use of Laboratory Animals, United States National Research Council, 2011). To evaluate the tumorigenic ability of LMNA-KD cells or sphere-derived adherent cells, the mice were injected subcutaneously into the left flank with various concentrations of cells (from $5 \times 10^4$ to $1 \times 10^7$ cells/mouse) in 200 μl of Matrigel (BD Biosciences-Discovery Labware). Each group included five mice. Tumor sizes were measured three times a week in two dimensions using a caliper, and tumor weight was calculated using the following formula: $a \times b^2/2$, where $a$ and $b$ are the long and short diameters of the tumor, respectively.

**Histopathological analysis**

The engrafted tumors were fixed with 4% phosphate-buffered formalin, and paraffin-embedded sections were stained using hematoxylin and eosin (H&E). The sections were then subjected to morphological analysis.

**miRNA assays**

Equal amounts of RNA were reverse transcribed with the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s instructions, with a custom 1X RT primer pool (hsa-miR-101–3p ID 002253; U6 snRNA ID 001973; hsa-miR-424 ID 000604; hsa-miR-34a ID 000426; hsa-miR-21 ID 000397; hsa-miR-504 ID 002084; hsa-miR-92a ID 000431). Real time PCR analysis was performed with an Applied Biosystems 7900HT thermal cycler using 20X Individual TaqMan® MicroRNA Assays.

**Hsa-miR-101 inhibitor and mimic**

SH-SY5Y control and LMNA-KD cells were seeded at a density of $5 \times 10^4$ cells/cm². After 24 h, the cells were transfected overnight in the presence of 10% FBS with mirVana miRNA inhibitor, miRNA mimic or the respective negative controls. Lipofectamine RNAiMAX Reagent (Life Technologies) was used as the transfection reagent, according to the manufacturer’s instructions. We transfected the has-miR-101 inhibitor (MH11414, Ambion) and the mimic (MC11414, Ambion) at a final concentration of approximately 50 nM. The mirVana miRNA inhibitor and mimic negative control were used at the same final concentration of 50 nM. Samples were harvested at 72 h to perform mRNA expression analysis.

**Statistical analysis**

Student’s $t$ test (unpaired, two-tailed) was used for statistical comparison of different tumor weights and between two groups. If there were more than two groups, we used the one-way ANOVA test.

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest.

**GRANT SUPPORT**

This study was partially supported by a Joint Grant CNR-EBRI ‘Molecular and cellular mechanisms of brain plasticity’ and by PNR-CNR Aging Program 2012–2014

**REFERENCES**

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3:203-216.
2. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller FD, Irwin MS, Thiele CJ and Kaplan DR. Neuroblastoma cells isolated from bone marrow metastases contain a
naturally enriched tumor-initiating cell. Cancer Res. 2007; 67:11234-11243.

3. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N and Cripe TP. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One. 2009; 4:e4235.

4. Coulon A, Flahaut M, Muhlethaler-Mottet A, Meier R, Liberman J, Balmas-Bourloud K, Nardou K, Yan P, Tercier S, Joseph JM, Sommer L and Gross N. Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia. 2013; 13:991-1004.

5. Maresca G, Natoli M, Nardella M, Arisi I, Trisciuglio D, Desideri M, Brandi R, D’Aguanno S, Nicotra MR, D’Onofrio M, Urbani A, Natali PG, Del BD, Felsani A and D’Agnano I. LMNA knock-down affects differentiation and progression of human neuroblastoma cells. PLoS One. 2012; 7:e45513.

6. Benavente R, Krohne G and Franke WW. Cell type-specific expression of nuclear lamina proteins during development of Xenopus laevis. Cell. 1985; 41:177-190.

7. Stick R and Hausen P. Changes in the nuclear lamina composition during early development of Xenopus laevis. Cell. 1985; 41:191-200.

8. Prokocimer M, Davidovich M, Nissim-Rafinia M, Wiesel-Motiuk N, Bar DZ, Barkan R, Meshorer E and Gruenbaum Y. Nuclear lamins: key regulators of nuclear structure and activities. J Cell Mol Med. 2009; 13:1059-1085.

9. Wu Z, Wu L, Weng D, Xu D, Geng J and Zhao F. Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma. J Exp Clin Cancer Res. 2009; 28:8.

10. Prokocimer M, Margalit A and Gruenbaum Y. The nuclear lamina and its proposed roles in tumorigenesis: projection on the hematologic malignancies and future targeted therapy. J Struct Biol. 2006; 155:351-360.

11. Zink D, Fischer AH and Nickerson JA. Nuclear structure in cancer cells. Nat Rev Cancer. 2004; 4:677-687.

12. Lund E, Guttering S, Calado A, Dahlberg JE and Kutay U. Nuclear export of microRNA precursors. Science. 2004; 303:95-98.

13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.

14. Chen Y and Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007; 67:976-983.

15. Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des. 2009; 15:456-462.

16. Foley NH, Bray JM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O’Meara A, O’Sullivan M and Stallings RL. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer. 2010; 9:83.

17. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M, Nimura Y, Osada H and Takahashi T. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene. 2007; 26:6099-6105.

18. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A and Berwanger B. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2008; 122:699-704.

19. Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaggstad T and Einvik C. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011; 105:296-303.

20. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignone C, Vacc a A and Ponzoni M. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogenic overexpression. Int J Cancer. 2002; 102:351-354.

21. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, Feygas A, Dalamagas T and Hatzigeorgiou AG. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res. 2015; 43(Database issue):D153-D159.

22. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J and Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene. 2008; 27:5204-5213.

23. Dalera P, Cho RW and Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007; 58:267-284.

24. Frank NY, Schatton T and Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010; 120:41-50.

25. Ward RJ and Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol. 2007; 2:175-189.

26. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ and Mongan NP. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009; 18:1093-1108.

27. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006; 38:431-440.
28. Ding XW, Wu JH and Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010; 86:631-637.

29. Zeng H, Park JW, Guo M, Lin G, Crandall L, Compton T, Wang X, Li XJ, Chen FP and Xu RH. Lack of ABCG2 expression and side population properties in human pluripotent stem cells. Stem Cells. 2009; 27:2435-2445.

30. Vermeulen L, Melo DSE, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G and Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010; 12:468-476.

31. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A and Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11:69-82.

32. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Donut G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69:1302-1313.

33. Eom YW, Oh JE, Lee JJ, Baik SK, Rhee KJ, Shin HC, Kim YM, Ahn CM, Kong JH, Kim HS and Shim KY. The role of growth factors in maintenance of stemness in bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun. 2014; 445:16-22.

34. Papanayotou C and Collignon J. Activin/Nodal signalling before implantation: setting the stage for embryo patterning. Philos Trans R Soc Lond B Biol Sci. 2014; 369.

35. Kelly DL and Rizzino A. DNA microarray analyses of genes regulated during the differentiation of embryonic stem cells. Mol Reprod Dev. 2000; 56:113-123.

36. Knoepfler PS. Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell. 2008; 2:18-21.

37. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC and Melton DA. “Stemness”: transcriptional profiling of embryonic and adult stem cells. Science. 2002; 298:597-600.

38. Tanaka N and Fukuzawa M. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int J Oncol. 2008; 33:815-821.

39. Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y, Hossain S, Akter J, Ogura A, Nakamura Y, Kadomatsu K and Nakagawara A. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Sci Rep. 2013; 3:3450.

40. Megison ML, Stewart JE, Nabers HC, Gillory LA and Beierle EA. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis. 2013; 30:555-568.

41. Guglielmi L, Cinnella C, Nardella M, Maresca G, Valentini A, Mercanti D, Felsani A and D’Agnano I. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. Cell Death Dis. 2014; 5:e1081.

42. Goodell MA. Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr Protoc Cytom. 2005; Chapter 9:Unit9.